UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

1 \ \ / 1 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	FO	R	M	8-	K
---	----	---	---	----	---

CURRENT REPORT	
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of	f 1934

June 14, 2022

Date of Report (Date of earliest event reported)

ETON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State of incorporation) 001-38738 (Commission File Number) 37-1858472 (I.R.S. Employer Identification Number)

21925 W. Field Parkway, Suite 235 Deer Park, Illinois 60010-7208 (Address of principal executive offices) (Zip code)

(847) 787-7361 (Registrant's telephone number, including area code)

(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, par value \$0.001 per share ETON NASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⊠

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

The 2022 Annual Meeting of Stockholders (the "Annual Meeting") of Eton Pharmaceuticals, Inc. (the "Company") was held on June 14, 2022 in Deer Park, Illinois. At the meeting, the Company's stockholders (1) elected the director nominee Paul V. Maier for a three-year term and (2) ratified the appointment of KMJ Corbin & Company LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022.

The results for each of the matters voted upon by the Company's stockholders at the Annual Meeting were as follows:

Proposal 1: Election of Directors

Nominee	For	Against	Abstain	Broker Non-Votes
Paul V. Maier	5,931,702	403,998	32,804	8,648,404

Proposal 2: Ratification of the Appointment of KMJ Corbin & Company LLP as the Company's Independent Registered Public Accounting Firm for the year ending December 31, 2022

For	Against	Abstain	Broker Non-Votes
14,483,058	496,263	37,287	0
		2	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 14, 2022 By: /s/ James R. Gruber

James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer)